Company Overview and News
Three 2x Leveraged High-Yield Monthly Pay Mortgage REIT ETNs all have very high yields, but at times may trade at prices which may present risk-free arbitrage opportunities.
SLDA DTK RC ABRN REM CMO TWO 8685 GPMT AJXA HASI ABR CEFL AVF DX AIG ABRN.CL AJX
2018-10-01 seekingalpha - 1
There is much uncertainty as to the future path of the equity and bond markets. This suggests diversification may be more important than usual.
STAR DTK ORC ABRN REM UBS CMO TWO AGNC HASI ABR AAL DX ARR ABRN.CL ULSGF
Oftentimes, high-ball stocks tend to steal more headlines than picks with single-digit prices. When a stock is nearing the $100 or $1,000 mark, it gets investors excited — just as the $1 trillion mark does for market cap. But the share price of a stock arguably only matters relative to, well, its own past or future.
SIRI ABR ABRN ABRN.CL SPOT AAPL CISN
2018-09-03 seekingalpha - 1
This ETN yields 20% based on recent prices. Investors are set to double their initial investment in less than 5 years.
CS STWD.WI FNMA FMCKI FMCKJ ABRN REM LADR TWO AGNC ABR FMCCO FMCCP FMCCM FMCCN NRZ FMCCI NLY FMCCJ FMCCG FMCKO FMCKP FMCKM FMCKN FMCKK CYS FMCKL FMCC ABRN.CL STWD FMCCS FMCCT
With an annualized yield of 21.9% on a monthly compounded basis, REML could be an attractive holding for those willing to accept the risks.
DGLD STAR ORC CS ABRN UGLD UBS AGNCP AGNC PII AGNCB ABR DSLV CEFL VIIX CSSLF VIIZ HOG CSGKF ARR ABRN.CL ZIV USLV TVIX ULSGF XIV
2018-08-17 seekingalpha - 2
MORL has had exceptional returns over the last five years, even though the Federal Reserve has raised rates seven times during that period.
ABR CEFL AVF STAR ORC AIG MORL ARR ABRN REM ABRN.CL UBS AGNC 8685 ULSGF
2018-08-11 investorplace - 1
But the one thing that they have in common is they all pay out 90% of their taxable income as dividends to shareholders. Traditionally, that has meant, as rents go up, dividends go up.
SSS ABR NRZ NSA STOR LSI ABRN LADR ABRN.CL LOAN CHCT CUBE
Arbor Realty Trust (NYSE:ABR) is a real estate investment trust (REIT) that is seeing a lot of interest in 2018. ABR stock is up 36% year to date and 42% for the past 12 months. That shows how much of a difference there is between last year and this year.
ABR ABRN ABRN.CL
2018-08-03 seekingalpha - 1
Arbor Realty Trust, Inc. (NYSE:ABR) Q2 2018 Earnings Conference Call August 3, 2018 10:00 AM ET
FNMA FMCKI FMCKJ ABRN ABR FMCCO FMCCP FMCCM FMCCN FMCCI FMCCJ FMCCG FMCKO FMCKP FMCKM FMCKN FMCKK FMCKL ABRN.CL FMCC FMCCS FMCCT
Arbor Realty Trust (ABR - Free Report) just came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.26 per share. This compares to earnings of $0.22 per share a year ago. These figures are adjusted for non-recurring items.
ABR ABRN CY ABRN.CL
Table of Contents
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to ABR / Arbor Realty Trust, Inc. on message board site Silicon Investor.
as of ET